Bio-Techne and 908 Devices Announce Joint Collaboration
Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) have announced a collaboration to develop a comprehensive protein characterization solution. This integration will combine Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip device. The partnership aims to streamline workflow for scientists, enhancing drug development efficiency via in-depth analysis of biotherapeutics. The combination of these technologies is expected to deliver faster commercialization, leveraging high-resolution separation techniques and mass spectrometry capabilities.
- Partnership between Bio-Techne and 908 Devices enhances protein characterization capabilities.
- The integration of Maurice icIEF and ZipChip minimizes sample prep and improves throughput.
- Expected advancement in drug development efficiency with additional high-resolution techniques.
- None.
MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple branded protein analysis portfolio of products, will pair its Maurice icIEF separation instrument with 908 Devices ZipChip device to deliver a seamless workflow for deeper protein characterization. Maurice and the iCE technology are the gold standard in protein characterization, providing absorbance and native fluorescence icIEF detection as well as CE-SDS, saving significant development time and reducing the time to commercialization.
908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, enables high-resolution separation and mass spec sample introduction with its plug-and-play open access platform ZipChip, which directly integrates electrospray ionization with mass spectrometry. The ZipChip integrates with Thermo Fisher, Sciex, and Bruker mass spectrometers and leverages Capillary Electrophoresis (CE) and electrospray ionization technology in order to minimize sample prep burden, perform high-resolution separations and directly introduce samples into a mass spec instrument.
Maurice paired with 908 Devices ZipChip allows in-depth characterization of biotherapeutics on an intact and near-native level. This workflow solution will increase scientists' drug development efficiency through additional rapid, high-resolution separation techniques coupled with mass spectrometry identification.
"We are very excited to collaborate with 908 Devices to provide an integrated workflow that enables fraction analysis for our Maurice users. Analyzing protein charge isoforms is a critical requirement and this enhanced capability using Maurice with the ZipChip and MS will provide a deeper understanding of a molecule through the various stages of development," stated Dave Eansor, President of Bio-Techne's Protein Sciences Segment. "Our iCE technology has been the gold standard in protein charge characterization for more than 20 years and this collaboration will provide additional value to the iCE community."
"By partnering with Bio-Techne and leveraging their market leading Maurice icIEF platform with our ZipChip device, we are together extending the workflow for customers conducting detailed protein characterization of charge variants," said Dr. Kevin J. Knopp, CEO and co-founder of 908 Devices. "This collaboration helps advance our reach into the biopharmaceutical market."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Investor Relations Contact:
David Clair, Senior Director, Investor Relations and Corporate Development
david.clair@bio-techne.com
612-656-4416
About 908 Devices
908 Devices (NASDAQ:MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.
908 Devices Contacts
Emily Fang
PAN Communications for 908 Devices
908devices@pancomm.com
Carrie Mendivil, IR@908devices.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-and-908-devices-announce-joint-collaboration-301281096.html
SOURCE Bio-Techne Corporation
FAQ
What is the collaboration between Bio-Techne and 908 Devices?
How will the Bio-Techne and 908 Devices partnership impact drug development?
What technologies are being combined in the Bio-Techne and 908 Devices partnership?
What are the expected benefits of the Bio-Techne and 908 Devices integration?
